A randomised clinical trial of high-intensity focused ultrasound ablation for the treatment of patients with localised breast cancer by Wu, F et al.
A randomised clinical trial of high-intensity focused ultrasound
ablation for the treatment of patients with localised breast cancer





1 and H Zhu
1
1Institute of Ultrasonic Engineering in Medicine, and Clinical Center for Tumor Therapy of 2nd Hospital, Chongqing University of Medical Sciences,
Box 153, 1 Medical College Road, Chongqing 400016, China
High-intensity focused ultrasound (HIFU) is a noninvasive treatment that induces complete coagulative necrosis of a tumour at depth
through the intact skin. This study was to explore the possibility of using HIFU for the treatment of patients with localised breast
cancer in a controlled clinical trial. A total of 48 women with biopsy-proven breast cancer (T1–2,N 0–2,M 0) were randomised to the
control group in which modified radical mastectomy was performed, and the HIFU group in which an extracorporeal HIFU ablation
of breast cancer was followed by modified radical mastectomy. Short-term follow-up, pathologic and immunohistochemical stains
were performed to assess the therapeutic effects on tumour and complications of HIFU. The results showed that no severe side
effect was observed in the HIFU-treated patients. Pathologic findings revealed that HIFU-treated tumour cells underwent complete
coagulative necrosis, and tumour vascular vessels were severely damaged. Immunohistochemical staining showed that no expression
of PCNA, MMP-9, and CD44v6 was detected within the treated tumour cells in the HIFU group, indicating that the treated tumour
cells lost the abilities of proliferation, invasion, and metastasis. It is concluded that, as a noninvasive therapy, HIFU could be effective,
safe, and feasible in the extracorporeal treatment of localised breast cancer.
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Breast cancer is the most common malignancy in women and, each
year, more than 1 million new cases of breast cancer are diagnosed
worldwide (McPherson et al, 2000). Radical and modified radical
mastectomy including axillary lymph node dissection has long been
regarded as appropriate therapies. During the last two decades,
significant advances have been made in the development of early
detection modalities and therapeutic methods. Breast conservation
surgery, combined with radiotherapy, chemotherapy, and hormo-
nal therapy, is performed with increasing frequency in patients
with early-stage breast cancer. The more from the mastectomy
toward breast conservation therapy has not changed long-term
survival rates of patients with breast cancer (Veronesi et al, 1993;
Fisher et al, 1995; Jacobson et al, 1995; Curran et al, 1998).
In spite of this progress, much remains to be achieved, and
major new therapies will be required to keep on the fight against
breast cancer. Recently, cryoablation (Staren et al, 1997), laser
(Robinson et al, 1998; Dowlatshahi et al, 2000), radiofrequency
(Bohm et al, 2000; McGahan et al, 2000), as minimally invasive
modalities, have been studied to explore the possibility of ablating
breast lesions. However, these alternative treatments require at
least percutaneous access and only destroy small lesion in the
management of breast tumours.
High-intensity focused ultrasound (HIFU) is a noninvasive
technique for the thermal ablation of solid tumours. Ultrasound
(US) beam can be focused and transmitted through solid tissues
within the body. This allows the possibility of using an
extracorporeal source of US for therapeutic purpose. With real-
time image guidance, HIFU could noninvasively induce complete
coagulative necrosis of a target tumour, without requiring surgical
exposure or insertion of instruments into the lesion. These
advantages make it one of the most attractive potential therapies
for the localised treatment of tumour. To our knowledge, most of
the studies on HIFU have been dealing with animal experiments in
which HIFU has induced target lesions at depth in tumour tissues
and normal organs, including liver, kidney, prostate, bladder, and
soft tissue (Chapelon et al, 1992; Chen et al, 1993; Sibille et al,
1993; Prat et al, 1995; Rowland et al, 1997).
Up to now, in the clinical application of HIFU ablation for
human breast tumour, Hynynen et al (2001) reported that 11
breast fibroadenomas in nine patients were treated with HIFU.
Eight of the 11 lesions treated with HIFU demonstrated complete
or partial ablation response. No adverse effects were detected,
except for one case of transient oedema in the pectoralis muscle 2
days after therapy. Huber et al (2001) used MRI-guided HIFU to
treat a 56-year-old patient with breast cancer. Postprocedural
pathologic examination indicated that HIFU induced lethal and
sublethal tumour ablation without damage to the surrounding
healthy tissue or systemic effects. However, to our knowledge, no
randomised clinical trial exists that explores the efficacy and safety
of HIFU in the treatment of patients with breast cancer, with
emphasis on the assessment of histological changes in the treated
tumour. In this paper, we studied the efficacy and safty of HIFU
treatment in a randomised controlled trial for the ablation of
patients with localised breast cancer. The purpose of this study was
to investigate the efficacy, safety, and feasibility of HIFU ablation
Received 24 April 2003; revised 26 August 2003; accepted 12
September 2003
*Correspondence: Dr F Wu; E-mail: mfengwu@yahoo.com
British Journal of Cancer (2003) 89, 2227–2233









lin the treatment of patients with localised breast cancer. This paper
reports the work in progress on this noninvasive modality, and it is
not our intention to compare it with other breast conservation




As described in detail previously (Wu et al, 2001a, 2002), the HIFU
therapeutic system used in this clinical trial of breast cancer
treatment principally consists of a diagnostic US device, units for
computer automatic control, six-direction movement, and a
therapeutic planning system, a US generator, integrated US
therapy transducers, and a degassed water circulation unit (see
Figure 1). The therapeutic US beam is produced by a 12-cm
diameter PZT-4 piezo-ceramic transducer with a focal length of
90mm, operating at a frequency of 1.6MHz. The focal region is
ellipsoid, with dimensions of 3.3mm along the beam axis and
1.1mm in the transverse direction.
An AU3 US imaging device (Esaote, Genoa, Italy) was used as
the real-time imaging unit of the system. This imaging probe (3.5–
5.0MHz) is situated at the centre of the HIFU transducer for real-
time guidance during HIFU procedure. The US beams of the
therapeutic transducer and the imaging probe completely overlap,
so that the longitudinal axis of HIFU beams is in the 2D US
imaging plane. The integrated transducer is attached to electric
motors, and can be moved smoothly in the six directions with
millimetric precision. Through computer control, the imaging
transducer was placed either against the skin or at a distance from
the skin in the water for pretreatment imaging. However, during
HIFU ablation, the imaging probe was usually situated in the water
apart from the skin.
Patients
A total of 48 women with biopsy-proven breast cancer were
selected for this clinical trial phase II. Before the beginning of this
study, the protocol design was approved by the ethics committee at
our university. In accordance with the specification stipulated by
the Helsinki Committee, an informed consent form was signed by
each patient at the time of enrollment after the principles of HIFU
thermal ablation had been completely described. The selection
criteria were as follows: histologically proven invasive breast
cancer (T1-2,N 0-2,M 0); single palpable tumours no greater than
6cm in diameter; the lesion boundaries visualised with color
Doppler US imaging, circumscribed at least more than 0.5cm from
skin or rib cage, and more than 2cm from nipple. All patients were
older than 18 years and had no breast implants. They had stable
haematogenic parameters, and no history of active myocardial
infarction within the past 6 months. They were randomised to two
treatment groups: the control group (n¼25), in which modified
radical mastectomy was performed without any intervention prior
to surgery; or the HIFU group (n¼23), in which extracorporeal in
situ ablation of the breast cancer with HIFU was followed by
modified radical mastectomy within 1–2 weeks. A 2-week follow-
up after HIFU treatment was performed to evaluate the potential
side effects of HIFU such as skin burns, local pain or discomfort,
mammary oedema, haemorrhage or infection, and fever. After
surgery, all patients received relevant doses of local radiation
therapy, conventional chemotherapy, and hormonal therapy, as
part of their adjuvant treatment.
Preoperative clinical assessments included the patient’s history,
a physical examination, haemotology tests, electrolytes, renal, and
liver function tests. Color Doppler US imaging of the diseased
breast, with a 10MHz linear array probe (Q-2000, Siemens,
Erlangen, Germany), was performed by a radiologist. Direct
visualisation of blood flow within the lesion was imaged by
adjusting color setting for optimal slow flow detection. If a patient
was recruited to receive the thermal ablation on the basis of the
images, US-guided core needle biopsy was performed to confirm
histological diagnosis. Technetium bone scanning and a chest
radiograph were required for the each case. A comparison of the
eligible patients’ characteristics in both groups, including age
distribution, tumour size, histologic diagnosis, node status, and
TNM classification, is shown in Table 1. Three of 23 patients in
HIFU group received one pre- and postprocedural magnetic
resonance imaging (1.0-T scanner, Impact, Siemens, Erlangen,
Germany). The MRI protocol included transverse conventional
spin echo (SE) T1-weighted image (WI), FSE T2-WI with fat
saturation and dynamic contrast-enhanced (Gadolinium,
0.2mlkg
 1, Magnevist, Berlex Laboratories, Wayne, USA). Two
radiologists reviewed the pre- and postprocedural MR imaging,
and reached a consensus in each patient.
HIFU 3D conformal treatment
In this study, real-time US imaging was utilised to monitor the
HIFU ablation procedure. It can accomplish three separate
functions, including real-time targeting of the tumour to be
treated, guidance of US energy deposition within the treated
region, and rapid real-time assessment of the volume of
coagulation necrosis during therapy. High-intensity focused
ultrasound treatment was performed in the patients under
intravenous sedation (N¼4) or general anaesthesia (N¼19).
During and following suitable anaesthesia, the patient was
monitored to track the blood pressure, pulse, respiration rate,
Figure 1 JC-HIFU therapeutic system for tumour (Chongqing HAIFUt
Technology Company, People’s Republic of China).
Table 1 Characteristics of eligible patients in both groups
Characteristics Control group HIFU group
No. of patients 25 23
Age (years) 45.571.2 46.571.7
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ltemperature, and peripheral oxygenation. Then, the patient was
placed prone and carefully positioned, so that the skin overlaying
to the lesion to be treated was easily in contact with degassed
water.
The coaxial US imaging device was used to establish the 3D
image of the whole tumour. For therapeutic purposes, the whole
tumour was divided into slices with 5mm separation using US
images. By scanning the HIFU beam in successive sweeps from the
deep to the shallow regions of the tumour, the targeted regions on
each slice were completely ablated. This process was repeated slice
by slice to achieve complete tumour ablation, in a manner
resembling that of cutting away slices of bread. In this study, the
extent of HIFU treatment was larger than the tumour extent, in
order to ensure the ablation of any adjacent microsatellites and to
obtain a sufficient tumour-free margin. It included the breast
lesion and its marginal breast tissue about 1.5–2.0cm around the
visible tumour. This is a principle that is routinely employed in
conventional surgery. During the HIFU treatment, each slice of US
images taken before and immediately after the treatment of each
slice were compared. These differences between treated and
untreated areas were used for monitoring the therapeutic effect.
In this study, the target tissue was exposed at acoustic focal peak
intensities from 5000 to 15000Wcm
 2. The scanning speed ranged
1–3mms
 1, and the track length was 20mm. High-intensity
focused ultrasound treatment time ranged from 45min to 2.5h
(median, 1.3h).
Pathologic examination
In the clinical trial, modified radical mastectomy was performed in
all of the eligible patients. In all, 23 patients in HIFU group
underwent the operation within 1–2 weeks after the thermal
ablation. All removed specimens including breast tumour and
normal breast tissue were evaluated by gross and histological
observations. They were serially sectioned at approximately 5mm
intervals and the slice thickness was measured. Gross observations
were recorded in a protocol containing the overall appearance,
size, and shape. By using a calipers, the visible lesions on each slice
were measured in both parallel and perpendicular axes, and
volume was calculated by multiplying the area by slice thickness.
Representative sections were prepared for routine microscopic
analysis. They were fixed in 10% phosphate-buffered formalin
(pH¼7), embedded in paraffin, cut at distances of 1mm in 4mm-
thick slices, and stained with haematoxylin and eosin (H&E). To
study the possibility of tumour vascular wall destruction induced
by HIFU ablation, elasticity fibrin and collagen fibrin double
staining (Victoria blue and ponceau’s histochemical staining) were
performed.
Immunohistochemistry
Immunohistochemistry was performed in all removed breast tissue
from eligible patients. Proliferating cell nuclear antigen (PCNA),
cell adhesion molecule CD44v6, and matrix metalloproteinase-9
(MMP-9) are molecular indicators that represent malignant
behaviours of breast cancer cell such as proliferation, invasion,
and metastasis, respectively. They were identified using the
biotin–streptavidin–peroxidase immunohistochemical technol-
ogy in treated breast cancer in the HIFU group, breast cancer in
the control group, and normal breast tissue from the HIFU group,
respectively. The paraffin-embedded breast specimens were
sectioned in 5-mm-thick slices.
The slices were deparaffinised in xylene, and rehydrated.
Endogenous peroxidase was blocked with 0.3% hydrogen peroxide
in methanol for 20min. Antigen retrieval was performed using
microwave heating. Subsequently, sections were preincubated with
1% bovine serum albumin. The primary antibodies used were
mouse monoclonal anti-human PCNA, anti-CD44v6, and anti-
MMP-9. All of them were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Sections were incubated at room
temperature with three kinds of the primary antibody, respectively,
followed by biotinylated second antibody incubation. The
chromogen was 3,3-diaminobenzidine tetrahydrochloride (brown).
Sections were incubated with phosphate-buffered saline, which
served as a negative control instead of the primary antibody.
The number of immunostained cells was counted in a
microscopic grid, 0.5 0.5mm
2 in size (0.25mm
2), using a
microscopic field of  200. A total of 10 areas with the most
abundant distribution were chosen in each case for this observa-
tion. Two independent observers judged the distribution of these
three variables and counted the positive cells. If the results were
inconsistent, the two observers discussed to reach a consensus on
the semi-quantitative scoring. For the PCNA, we used the labelling
index of PCNA in cancer cells to evaluate the result. The number of
PCNA
þ cancer cells was counted among 100 cancer cells using a
 200 microscopic field.
Statistical analysis
All observed data are displayed as the mean value plus or minus
the standard deviation. The statistical significance of any observed
difference between the mean values of control and treatment
groups was evaluated using an unpaired Student’s t-test. The
variability in data was compared with the F test for variance. The
differences in percentage data were analysed by using the Fisher’s




Among 23 patients, 16 cases underwent surgery at 7–10 days after
HIFU ablation, and the remaining seven patients were operated at
11–14 days. After HIFU, oedema was noted in the mammary tissue
surrounding the treated tumour. In all cases, the treated area
included the tumour and a 1.5–2.0cm margin of normal breast
tissue around the tumour. At 7–10 days postoperatively, the
oedema gradually disappeared. In total, 14 patients experienced
mild local pain, warmth, and sensation of heaviness in the diseased
breast. But only four patients were given 3–5 days prescription for
oral analgesics. One patient had minimal skin burn, which had
entirely recovered by 10 days post-HIFU. There was no incidence
of bleeding or infection of the treated breast requiring interven-
tion. Three patients received one MRI examination after HIFU
treatment. Compared with preprocedural images, enhanced MRI
revealed the absence of contrast enhancement in the treated region
including tumour and 1.5–2.0cm normal breast tissue surround-
ing the tumour (see Figure 2), indicative of coagulative necrosis.
Pathologic examination
All treated tumours in the 23 patients were confirmed by gross
observation after removal of the diseased breast. Neither bleeding
of the treated regions nor injury of intervening tissues was
identified, indicating the safety of HIFU ablation. Macroscopic
examination showed that HIFU treatment induced complete
coagulative necrosis of the target tissue, which included the
tumour and a mean margin of 1.8070.58cm (range from 1.5 to
2.2cm) of an obviously normal breast tissue surrounding the
tumour. This felt firmer on palpation than normal tissue. At the
margin between the treated and untreated regions, there was a rim
of congestion that represented an inflammatory reaction to
thermal ablation. Histological examination revealed homogeneous
coagulative necrosis, including the tumour and normal breast
tissue within the target region. Figure 3 shows that the tumour cells
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lof breast cancer treated with HIFU were very abnormal, with the
appearance of irreversible cell death, as demonstrated by pyknotic
nuclei, nuclear disruption, and disappearance. Variable amounts
of granulation tissue were noted with the presence of immature
fibroblasts, inflammatory cells, and new capillaries in the
boundary region. Compared with blood vessels in the control
group, vascular structure in the HIFU group was seriously
damaged. Appearances were of indistinct cellular margins,
endothelial disruption, and nuclear disappearance, and destruction
of tunica media, indicative of coagulative necrosis (Figure 4). The
size of the destroyed vessels was less than 2mm in diameter,
including the arteries and veins. Scattered intravascular thrombi
were often observed in the destroyed vessels. Victoria blue and
ponceau’s histochemical staining showed that vascular elasticity
fibrin and collagen fibrin were significantly collapsed and
disrupted, as shown in Figure 4.
Immunohistochemical staining
Figure 5 showed immunohistochemical staining for PCNA,
CD44v6, and MMP-9 in breast cancer in the control group, normal
mammary tissue, and treated breast cancer in the HIFU group,
respectively. The percentages of the PCNA labelling index in the
normal breast tissue, breast cancer, and HIFU-treated tumour were
6, 44, and 0%. CD44v6-positive cells were present in 56% of
tumour samples in the control group (n¼14), and 4.5% of normal
breast tissue (n¼1). But, in the HIFU group, CD44v6-positive cells
Figure 2 Contrast-enhanced MRI of a left breast cancer (arrowed) in a
36-year-old woman before (A) and 1 week after (B) HIFU ablation. Note
the absence of contrast uptake in ablated volume, including tumour and a
margin of treated normal breast tissue about 1.5–2.0cm around the
cancer. Oedema is observed in the mammary tissue surrounding the
treated region.
Figure 3 Microscopic changes of tumour cells in patients with breast
cancer treated by HIFU. (A) Untreated viable breast cancer cells. (B–D):
Necrosed tumour cells represented by pyknotic nuclei (B); nuclear
disruption (C); and nuclear disappearance (D). H&E staining  400.
Figure 4 Microscopic changes of tumour vascularity in patients with
breast cancer treated by HIFU. (A) Untreated tumour blood vessels; (B)
destruction of tumour vascularity with disruption of the endothelium and
tunica media, H&E staining  400. (C) untreated tumour vessel wall; (D)
destroyed tumour blood vessels with the collapse and disruption of
vascular elasticity fibrin and collagen fibrin, Victoria blue and ponceau’s
histochemical staining  400.
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lwere not detected within the treated breast cancer (n¼0).
CD44v6
þ cell density was significantly higher in tumour than in
the normal breast tissue (Po 0.01), but in the HIFU group the
proportion of these membrane-positive cancer cells was 0%.
Compared with 60% of MMP-9 within breast cancer in the control
group (n¼15), no MMP-9
þ cancer cells were detected in either
normal breast cancer or treated breast cancer (n¼0), as shown in
Table 2.
DISCUSSION
The energy deposition of focused US on the target tissue causes
coagulative necrosis of tumours (Chapelon et al, 1992; Chen et al,
1993; Sibille et al, 1993; Prat et al, 1995; Rowland et al, 1997). In
this study, pathological examination revealed that both breast
cancer cells and normal tissues within the treated region presented
a typical appearance of coagulative necrosis with severe nuclear
damage. Furthermore, tumour vessels were severely damaged in
the patients with breast cancer, resulting in significant vascular
disruption and vessel occlusion. By using immunohistochemical
staining, we found that no expression of PCNA, CD44v6, and
MMP-9 of the treated tumour cells was identified in the HIFU
group, unlike those in the control group. These findings indicated
that the treated breast cancer cells presented had not only
undergone coagulative necrosis in histology, but also the absence
of malignant behaviours such as proliferation, invasion, and
metastasis.
The goal of our clinical study is to explore the efficacy, safety,
and feasibility of extracorporeal HIFU ablation for primary breast
cancer. To achieve this purpose, we hypothesise that both tumour
and some normal breast tissue surrounding the tumour should be
completely destroyed with focused US energy. This larger ablation
extent would guarantee an adequate ‘surgical’ HIFU margin
surrounding the tumour, and would be required if HIFU therapy
is considered as an alternative to surgical procedure. This principle
is routinely used in conventional surgery in order to ensure the
removal of adjacent microsatellites, and to allow for uncertainty
that frequently exists concerning the exact location of definite
tumour margins. In the clinical study, histological examination
revealed that HIFU induced coagulative necrosis of the target
tumour and its surrounding normal tissue by about 1.5–2.2cm
(mean 1.8070.58cm), which corresponded closely with the
pretreatment extent (1.5–2.0cm around the tumour) determined
in the therapeutic protocol before HIFU procedure. This result
indicated that, with real-time US guidance, HIFU can precisely
cause a complete necrosis of target tissue, including the tumour
and normal tissue.
In clinical applications, real-time imaging modalities including
both US (Vallancien et al, 1996; Beerlage et al, 1999; Chapelon et al,
1999; Gelet et al, 1999; Wu et al, 2001a, 2002; Uchida et al, 2002)
and MRI (Huber et al, 2001; Hynynen et al, 2001) can guide HIFU
ablation of solid tumours. These imaging techniques have been
used for targeting the lesion to be treated, monitoring the
therapeutic procedure, assessing the thermal effects on target
tissue, and controlling the ultrasonic energy. In this study, the
reasons for choosing real-time US for the guidance of HIFU
treatment were as follows: low cost, flexibility, speed of image
processing, and extensive availability. During the HIFU procedure,
obvious changes in grey scale within the target tissue were
immediately detected on the US image after HIFU ablation. Our
previous studies indicated that these hyperechoic zones corre-
sponded well to the extent of coagulative necrosis, and that there
was a close relationship between the extent of necrosis as measured
by gross examination and the hyperechoic extent measured on the
US image immediately after FUS in both in vivo and in vitro tissues
(Wang et al, 1997; Wu et al, 1998, 2000, 2001b; Bai et al, 1999). In
the clinical treatment of patients with breast cancer, we also found
that the hyperechogenic regions were regular in shape and size,
and conformed to the extent of coagulative necrosis induced by
HIFU ablation (Liu et al, 1998; Cao et al, 2001; Wu et al, 2001;
Zhou et al, 2001). Although the mechanism for tissue grey-scale
change is still unclear, US effects on tissue such as heating and
cavitation are involved in the formation of coagulative necrosis,
and real-time diagnostic US guidance is seen to be useful in the
detection of the coagulative necrosis of target tissue during HIFU
procedures.
As a noninvasive method, HIFU has a potential application in
the treatment of patients with breast cancer. However, some
problems still exist with this technique. First, to our knowledge,
neither MRI nor diagnostic US have satisfactory sensitivity for




Untreated breast Treated breast
 Normal breast cancer  cancer 
Figure 5 Immunohistochemistry for PCNA (the first row), CD44v6 (the
second row), and MMP-9 (the third row) in the patients with breast cancer
treated by HIFU (S-P staining,  400). The immunoreactivity is shown by
the color brown. From left to right, each separated morphology is
represented by a normal breast tissue in the HIFU group, untreated cancer
cells in the control group, and treated cancer in the HIFU group,
respectively. Compared with untreated cancer cells, no positive cells of
PCNA, CD44v6, and MMP-9 within the treated cancer cells were observed
in the HIFU group.







Normal breast tissue 6 4.5 0
Untreated breast cancer 44 56 60
Treated breast cancer 0 0 0
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limaging modality for pretreatment demonstration of tumour
extent is not currently available. Therefore, in our clinical study,
image-detected breast cancer and 1.5–2.0cm normal tissue
surrounding the cancer were completely ablated to allow for the
uncertainty that frequently exists concerning the exact location of
definite tumour margins. However, for some superficial lesions
close to the skin, there is a possibility of causing skin burns, or
leaving residual viable tumour cells if the overlying skin is left
undamaged. A second problem is that a palpable firm lump would
persist in the treated region for a period of time after HIFU
treatment. This lump may not be satisfactory or cosmetically
desirable for the patient, although the tissue would revert to benign
status. This could also cause potential problems with follow-up
images, in distinguishing whether there is local recurrence
postoperatively. Finally, a suitable indication of HIFU ablation
for breast cancer is essential if this technique can be used in
clinical practice. Breast tumours with undefined margins, scattered
multiple foci, and tumours close to the nipple should be excluded
as potential targets for HIFU.
In conclusion, this study demonstrates for the first time that
US-guided HIFU is effective, safe, and feasible in the treatment
of localised breast cancer with well-demarcated margins.
However, much supplementary investigation is necessary to
explore these above problems, and large controlled clinical trials
must be performed before extracorporeal HIFU can be recom-
mended as a conserving breast modality in the treatment of breast
cancer.
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